Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2010 1
2011 1
2012 1
2013 5
2014 2
2015 1
2016 1
2017 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19.
Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, Saggar R. Singh D, et al. Among authors: pfeifer nd. Eur Respir J. 2021 Oct 14;58(4):2100673. doi: 10.1183/13993003.00673-2021. Print 2021 Oct. Eur Respir J. 2021. PMID: 34210790 Free article. Clinical Trial. No abstract available.
13 results